Jubilant Life Sciences Limited Risk Report

⚖️ Legal & Regulatory

Jubilant Life Sciences has encountered several legal and regulatory challenges that could impact its business operations. The company's Roorkee plant faced regulatory scrutiny, which required attention to regulatory compliance. Additionally, financial settlements and strategic partnerships shaped its regulatory landscape over the years.

• Jubilant Life Sciences settled a loan with IFC through a USD 135 million payout 🗓 March 29, 2019.
• The USFDA recommended regulatory action against Jubilant Life's Roorkee plant 🗓 December 8, 2018.
• SEBI imposed a penalty of Rs 50 lakh on Jubilant Life Sciences for unspecified reasons 🗓 January 31, 2018.
• Jubilant Life Sciences had to address concerns following a USFDA warning on its Nanjangud facility, indicating ongoing compliance issues 🗓 March 22, 2019.

📜 Innovation & R&D

Jubilant Life Sciences has actively engaged in innovation and research to expand its portfolio and market presence. The company frequently collaborates with partners to enhance its product offerings and has achieved significant milestones in its R&D initiatives.

• Jubilant Life Sciences selected CDD Vault to handle research communication for five years 🗓 May 8, 2019, aiming to improve collaboration and data management.
• Jubilant launched a generic version of Remdesivir for COVID-19 treatment 🗓 August 4, 2020, addressing urgent healthcare needs during the pandemic.
• The company entered several licensing agreements with Gilead to produce Remdesivir 🗓 May 12, 2020, highlighting its strategic moves in pharmaceuticals.
• Jubilant announced plans to launch Jubi-R for COVID-19 treatment 🗓 August 4, 2020, broadening its COVID-19 related offerings.